Cynata Completes Phase 1 GvHD Clinical Trial Follow-up with Positive Results
30 juil. 2020 08h02 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, July 30, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell...
Cynata Announces Ethics Approval and Expedited Regulatory Pathway for Phase 3 Osteoarthritis Clinical Trial
18 juin 2020 08h02 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, June 18, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell...
Cynata Receives Ethics Approval to Commence Clinical Trial in COVID-19 and Clinical Development Update
08 mai 2020 08h05 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, May 08, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics,...
Preclinical Study Showing Beneficial Effects of Cymerus™ MSCs in Acute Respiratory Distress Syndrome Accepted for Publication in Leading Peer-Reviewed Journal
17 avr. 2020 08h15 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, April 17, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
Market Update and Additional A$618k R&D Tax Refund
11 mars 2020 08h30 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, March 11, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
14 janv. 2020 08h05 HE
|
Cynata Therapeutics Limited
MELBOURNE, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has...
Cymerus™ MSCs Effective in Preclinical Model of Sepsis
05 déc. 2019 08h30 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received positive...
Cynata Files Application to Commence Phase 2 Clinical Trial in Critical Limb Ischaemia
25 nov. 2019 08h15 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has filed a Clinical...
Cynata Advances Toward Phase 2 Clinical Trial of Cymerus(TM) MSCs in Patients with Osteoarthritis
04 oct. 2019 08h05 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to provide an...
Fujifilm Exercises License Option in GvHD
17 sept. 2019 08h15 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that...